Adjuvant therapy in renal cell carcinoma - Past, present, and future

Seminars in Oncology

Volumn 40, Issue 4, 2013, Pages 482-491

  Janowitz, Tobias ^a   Welsh, Sarah J ^a   Zaki, Kamarul ^a   Mulders, Peter ^b   Eisen, Tim ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AXITINIB; BCG VACCINE; BEVACIZUMAB; CANCER VACCINE; CELECOXIB; DOCETAXEL; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; GIRENTUXIMAB; INTERLEUKIN 2; MEDROXYPROGESTERONE ACETATE; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VITESPEN; ZOLEDRONIC ACID;

ANOREXIA; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG BIOAVAILABILITY; DRUG MEGADOSE; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INTENTION TO TREAT ANALYSIS; KIDNEY CARCINOMA; LIVER TOXICITY; MICROMETASTASIS; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); NEPHRECTOMY; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TUMOR NECROSIS; TUMOR RECURRENCE;

CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; RESEARCH DESIGN;

EID: 84883177229     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.05.004     Document Type: Article

References (48)

1. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 12 2010 2893 2917
2. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2 2011 69 90
3. W.H. Chow, S.S. Devesa, J.L. Warren, and J.F. Fraumeni Rising incidence of renal cell cancer in the United States JAMA 281 17 1999 1628 1631
4. C.J. Kane, K. Mallin, J. Ritchey, M.R. Cooperberg, and P.R. Carroll Renal cell cancer stage migration: analysis of the National Cancer Data Base Cancer 113 1 2008 78 83
5. B. Escudier, T. Eisen, and C. Porta Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 suppl 7 2012 vii65-vii71
6. I. Frank, M.L. Blute, J.C. Cheville, C.M. Lohse, A.L. Weaver, and H. Zincke An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score J Urol 168 6 2002 2395 2400
7. B.C. Leibovich, M.L. Blute, and J.C. Cheville Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials Cancer 97 7 2003 1663 1671
8. J.-J. Patard, H.L. Kim, and J.S. Lam Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study J Clin Oncol 22 16 2004 3316 3322
9. A. Zisman, A.J. Pantuck, and F. Dorey Improved prognostication of renal cell carcinoma using an integrated staging system J Ci Oncol 19 6 2001 1649 1657
10. V. Ficarra, G. Novara, and A. Galfano The "Stage, Size, Grade and Necrosis" score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma BJU Int 103 2 2009 165 170
11. J.R. Quesada, D.A. Swanson, and J.U. Gutterman Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report J Clin Oncol 3 8 1985 1086 1092
12. J.S. Horoszewicz, and G.P. Murphy An assessment of the current use of human interferons in therapy of urological cancers J Urol 142 5 1989 1173 1180
13. S.A. Rosenberg, J.C. Yang, and S.L. Topalian Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 JAMA 271 12 1994 907 913
14. D.T. Sleijfer, R.A. Janssen, J. Buter, E.G. De Vries, P.H. Willemse, and N.H. Mulder Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis J Clin Oncol 10 7 1992 1119 1123
15. G. Pizzocaro, L. Piva, and M. Colavita Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study J Clin Oncol 19 2 2001 425 431
16. E.M. Messing, J. Manola, and G. Wilding Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial J Clin Oncol 21 7 2003 1214 1222
17. J.I. Clark, M.B. Atkins, and W.J. Urba Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a Cytokine Working Group randomized trial J Clin Oncol 21 16 2003 3133 3140
18. R. Passalacqua, C. Buzio, and S. Buti Adjuvant low-dose interleukin-2 (IL2) plus interferon-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC) J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I 25 2007 18S
19. J. Atzpodien, H. Kirchner, and H.J. Illiger IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial Br J Cancer 85 8 2001 1130 1136
20. J. Atzpodien, H. Kirchner, and U. Jonas Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) J Clin Oncol 22 7 2004 1188 1194
21. J. Atzpodien, E. Schmitt, and U. Gertenbach Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) Br J Cancer 92 5 2005 843 846
22. M. Aitchison, C. Bray, H. Van Poppel, R. Sylvester, J. Graham, C. Innes, and L.V.P. McMahon Preliminary results from a randomized phase III trial of adjuvant interleukin-2, interferon alpha and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC) J Clin Oncol 26 suppl 2008 5040 abstr
23. H. Van Poppel, S. Joniau, and S.W. Van Gool Vaccine therapy in patients with renal cell carcinoma Eur Urol 55 6 2009 1333 1342
24. E. Galligioni, M. Quaia, and A. Merlo Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study Cancer 77 12 1996 2560 2566
25. A. Adler, G. Gillon, and H. Lurie Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects J Biol Response Modifiers 6 6 1987 610 624
26. C. Wood, P. Srivastava, and R. Bukowski An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial Lancet 372 9633 2008 145 154
27. D. Jocham, A. Richter, and L. Hoffmann Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial Lancet 363 9409 2004 594 599
28. M. Fishman, and S. Antonia Specific antitumour vaccine for renal cancer Lancet 363 9409 2004 583 584
29. J.P. Karr, J.E. Pontes, S. Schneider, A.A. Sandberg, and G.P. Murphy Clinical aspects of steroid hormone receptors in human renal cell carcinoma J Surg Omcol 23 2 1983 117 124
30. G. Pizzocaro, L. Piva, and G. Di Fronzo Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study J Urol 138 6 1987 1379 1381
31. S.D. Fosså, I. Kjølseth, and G. Lund Radiotherapy of metastases from renal cancer Eur Urol 8 6 1982 340 342
32. M. Kjaer, P.L. Frederiksen, and S.A. Engelholm Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group Int J Radiat Oncol Biol Phys 13 5 1987 665 672
33. M. Kjaer, P. Iversen, and V. Hvidt A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group Scand J Urol Nephrol 21 4 1987 285 289
34. F. Latif, K. Tory, and J. Gnarra Identification of the von Hippel-Lindau disease tumor suppressor gene Science (New York, NY) 260 5112 1993 1317 1320
35. P.H. Maxwell, M.S. Wiesener, and G.W. Chang The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 399 6733 1999 271 275
36. H. Zhong, K. Chiles, and D. Feldser Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics Cancer Res 60 6 2000 1541 1545
37. S.M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J.M. Llovet, and M. Lynch Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Molecular cancer therapeutics 7 10 2008 3129 3140
38. B. Escudier, T. Eisen, and C. Porta Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 23 suppl 7 2012 vii65-vii71
39. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 2008 449 456
40. B.I. Rini, B. Escudier, and P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 9807 2011 1931 1939
41. S. Pyrhoenen, and M.A. Board Press release WILEX AG announces results of phase III ARISER study with RENCAREX in clear cell renal cell carcinoma 2012 1 3 October
42. T. Eisen, C.N. Sternberg, and C. Robert Targeted therapies for renal cell carcinoma: review of adverse event management strategies J Natl Cancer Inst 104 2 2012 93 113
43. R. Figlin, C. Sternberg, and C.G. Wood Novel agents and approaches for advanced renal cell carcinoma J Urol 188 3 2012 707 715
44. S.J. Welsh, T. Janowitz, and T. Eisen The future of adjuvant therapy for renal cell carcinoma Clin Pract 9 4 2012 451 462
45. J.R. Brahmer, S.S. Tykodi, and L.Q.M. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N EnglJ Med 366 26 2012 2455 2465
46. J.M.S. Wason, and T. Jaki Optimal design of multi-arm multi-stage trials Stat Med 31 30 2012 4269 4279
47. N.D. James, M.R. Sydes, and N.W. Clarke STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer - a multi-arm multi-stage randomised controlled trial Clin Oncol (Royal College of Radiologists (Great Britain)) 20 8 2008 577 581
48. S. Welsh, T. Eisen, and T. Janowitz Focus on renal cancer Antiangiogenesis in Cancer Therapy 2013